1. Computational analysis of antibody dynamics identifies recent HIV-1 infection
- Author
-
Seaton, Kelly E, Vandergrift, Nathan A, Deal, Aaron W, Rountree, Wes, Bainbridge, John, Grebe, Eduard, Anderson, David A, Sawant, Sheetal, Shen, Xiaoying, Yates, Nicole L, Denny, Thomas N, Liao, Hua-Xin, Haynes, Barton F, Robb, Merlin L, Parkin, Neil, Santos, Breno R, Garrett, Nigel, Price, Matthew A, Naniche, Denise, Duerr, Ann C, Keating, Sheila, Hampton, Dylan, Facente, Shelley, Marson, Kara, Welte, Alex, Pilcher, Christopher D, Cohen, Myron S, and Tomaras, Georgia D
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,HIV/AIDS ,Sexually Transmitted Infections ,Vaccine Related ,Biotechnology ,Infectious Diseases ,Vaccine Related (AIDS) ,Prevention ,Immunization ,Infection ,Good Health and Well Being ,Antibody Affinity ,Antigen-Antibody Reactions ,Biomarkers ,Computational Biology ,HIV Antibodies ,HIV Antigens ,HIV Infections ,HIV-1 ,Humans ,Immunoglobulin G ,Incidence ,Retrospective Studies ,Time Factors ,CEPHIA group ,AIDS/HIV ,Antigen ,Immunoglobulins ,Biomedical and clinical sciences ,Health sciences - Abstract
Accurate HIV-1 incidence estimation is critical to the success of HIV-1 prevention strategies. Current assays are limited by high false recent rates (FRRs) in certain populations and a short mean duration of recent infection (MDRI). Dynamic early HIV-1 antibody response kinetics were harnessed to identify biomarkers for improved incidence assays. We conducted retrospective analyses on circulating antibodies from known recent and longstanding infections and evaluated binding and avidity measurements of Env and non-Env antigens and multiple antibody forms (i.e., IgG, IgA, IgG3, IgG4, dIgA, and IgM) in a diverse panel of 164 HIV-1-infected participants (clades A, B, C). Discriminant function analysis identified an optimal set of measurements that were subsequently evaluated in a 324-specimen blinded biomarker validation panel. These biomarkers included clade C gp140 IgG3, transmitted/founder clade C gp140 IgG4 avidity, clade B gp140 IgG4 avidity, and gp41 immunodominant region IgG avidity. MDRI was estimated at 215 day or alternatively, 267 days. FRRs in untreated and treated subjects were 5.0% and 3.6%, respectively. Thus, computational analysis of dynamic HIV-1 antibody isotype and antigen interactions during infection enabled design of a promising HIV-1 recency assay for improved cross-sectional incidence estimation.
- Published
- 2017